BRAF and melanoma: Based on these molecular characteristics of the melanoma, specific BRAF (V600E) ATP-competitive inhibitors, such as vemurafenib [5] or dabrafenib [6] have been developed and have shown remarkable clinical efficacy in BRAF(V600E) melanoma tumors.